Seres Therapeutics announced that its Phase 1b trial of SER-155 showed a 77% reduction in bloodstream infections, with the results published in Nature Medicine.
Seres Therapeutics announced the results of its Phase 1b clinical trial of SER-155, reporting a 77% reduction in bloodstream infections. The results were published in Nature Medicine.
According to the announcement, the study was conducted by the company’s research team based in Cambridge, Massachusetts, and suggested that SER-155 may significantly reduce the incidence of bloodstream infections. The company is also listed as NASDAQ:MCRB.